Share on StockTwits

AstraZeneca plc (NYSE:AZN)‘s stock had its “underweight” rating restated by JPMorgan Chase & Co. in a research note issued on Thursday, American Banking News reports.

AZN has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Friday, April 11th. They now have a $67.00 price target on the stock. Separately, analysts at Panmure Gordon upgraded shares of AstraZeneca plc from a “sell” rating to a “hold” rating in a research note on Tuesday, April 1st. Finally, analysts at Morgan Stanley downgraded shares of AstraZeneca plc to an “underweight” rating in a research note on Thursday, March 13th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. AstraZeneca plc has an average rating of “Hold” and a consensus target price of $63.00.

AstraZeneca plc (NYSE:AZN) opened at 63.49 on Thursday. AstraZeneca plc has a 1-year low of $46.87 and a 1-year high of $68.76. The stock’s 50-day moving average is $65.23 and its 200-day moving average is $59.70. The company has a market cap of $79.818 billion and a price-to-earnings ratio of 31.14.

AstraZeneca plc (NYSE:AZN) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.23 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.22 by $0.01. The company had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter last year, the company posted $1.56 earnings per share. AstraZeneca plc’s revenue was down 6.0% compared to the same quarter last year. Analysts expect that AstraZeneca plc will post $4.27 EPS for the current fiscal year.

AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.